低剂量率前列腺近距离放疗中活检组织Gleason模式4估计绝对百分比(eAPP4):在一个大型队列中评估其预后价值
本研究回顾性分析了497例接受低剂量率种子近距离放疗的中危前列腺癌患者,利用活检各针芯的Gleason分级分组与优化的模式4百分比估计值计算eAPP4。中位随访7.3年,eAPP4可预测累积复发率(p=0.003)、复发治疗(p=0.003)和无转移生存(p=0.001),而单独Gleason分级分组无预测价值。
要点
- eAPP4可预测中危前列腺癌LDR-BT后的复发和无转移生存。
- 单独Gleason分级分组未能预测上述结局。
- 采用30%(GG2)和80%(GG3)估计值时eAPP4对MFS预测最强(HR 1.07)。
核心结论
- eAPP4在大型接受LDR-BT的中危前列腺癌队列中强烈预测复发和无转移生存。
- 作者认为未来中危前列腺癌患者的治疗可包括使用eAPP4进行预后判断。
研究设计与样本
- 回顾性综述497例已知分级分组2或3、接受低剂量率种子近距离放疗的中危前列腺癌患者,治疗地点为一家四级癌症中心。
- 每例患者的前列腺活检采用synoptic报告进行Gleason分级,但未包含样本中模式4疾病的百分比;每针芯被赋予分级分组,并结合优化的模式4疾病百分比估计值计算eAPP4。
- 评估的结局包括累积复发率(CIR)、复发疾病治疗(RRX)和无转移生存(MFS)。
主要发现
- 428例(86%)患者为Gleason分级分组2,69例(14%)为分级分组3。
- 230例(46%)患者基线为NCCN有利中危,267例(54%)为NCCN不利中危。
- 中位随访7.3(5.5-9.6)年。
- eAPP4可预测CIR(p=0.003)、RRX(p=0.003)或MFS(p=0.001)事件,而单独Gleason分级分组则不能。
- 当使用30%(分级分组2)和80%(分级分组3)的估计值时,eAPP4对MFS的预测最强[HR 1.07(1.03-1.12);p=0.001]。
临床怎么用
- 作者认为未来中危前列腺癌患者的治疗可包括使用eAPP4进行预后判断。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine whether a system to estimate Absolute Percentage of Biopsied Tissue Positive for Gleason Pattern 4 (eAPP4) is useful as a prognostication tool for patients with intermediate risk prostate cancer (IR-PCa) undergoing low dose rate prostate brachytherapy. METHODS: 497 patients with IR-PCa and known grade group 2 or 3 disease treated with low dose rate seed brachytherapy (LDR-BT) at a quaternary cancer centre were retrospectively reviewed. Prostate biopsies for each patient included Gleason grading with synoptic reporting that did not include percentage of pattern 4 disease found within the sample. Each core was assigned a grade grouping, however, and that was used with optimized estimates of percentage of pattern four disease to estimate eAPP4. Outcomes including cumulative incidence of recurrence (CIR), treatment of recurrent disease (RRX), and metastasis-free survival (MFS) were then reviewed and the prognostic value of eAPP4 evaluated. RESULTS: 428 (86%) patients had Gleason grade group 2 and 69 (14%) patients had Gleason grade group 3 disease. 230 (46%) patients had National Comprehensive Cancer Network (NCCN) favourable intermediate at baseline, while 267 (54%) of patients had NCCN unfavourable intermediate at baseline. Median follow-up was 7.3 (5.5-9.6) years. eAPP4 was predictive of CIR (p = 0.003), RRX (p = 0.003), or MFS (p = 0.001) events, while Gleason grade grouping alone was not. eAPP4 was strongest as a predictor for MFS when estimates of 30% (grade group 2) and 80% (grade group 3) were used [HR 1.07 (1.03-1.12); p = 0.001]. CONCLUSIONS: eAPP4 was strongly predictive of recurrence and metastasis-free survival in a large cohort of patients receiving LDR-BT treatment for IR-PCa. Treatment of future patients with IR-PCa could include the use of eAPP4 prognostication.
引用
- Casey G, Quon H, Meyer T, et al. Estimated absolute percentage of biopsied tissue positive for Gleason pattern 4 (eAPP4) in low dose rate prostate brachytherapy: Evaluation of prognostic utility in a large cohort. Radiother Oncol. 2023. PMID: 37604278. doi:10.1016/j.radonc.2023.109859
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。